Hologic, Inc. (NASDAQ:HOLX) Director Lawrence M. Levy sold 9,193 shares of the company’s stock in a transaction that occurred on Wednesday, May 24th. The stock was sold at an average price of $42.93, for a total value of $394,655.49. Following the transaction, the director now directly owns 46,206 shares of the company’s stock, valued at $1,983,623.58. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Shares of Hologic, Inc. (NASDAQ:HOLX) traded down 0.53% during mid-day trading on Friday, reaching $43.27. The company’s stock had a trading volume of 209,265 shares. The company’s 50-day moving average is $43.70 and its 200 day moving average is $41.06. The firm has a market capitalization of $12.12 billion, a P/E ratio of 15.51 and a beta of 1.10. Hologic, Inc. has a 1-year low of $32.64 and a 1-year high of $46.05.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, May 10th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.46 by $0.04. The company had revenue of $715.40 million during the quarter, compared to analyst estimates of $685.24 million. Hologic had a return on equity of 27.17% and a net margin of 11.57%. The company’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.47 earnings per share. On average, analysts expect that Hologic, Inc. will post $2.01 earnings per share for the current year.

Insider Buying and Selling by Quarter for Hologic (NASDAQ:HOLX)

TRADEMARK VIOLATION WARNING: “Hologic, Inc. (HOLX) Director Lawrence M. Levy Sells 9,193 Shares” was originally reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/05/26/hologic-inc-holx-director-lawrence-m-levy-sells-9193-shares.html.

Several research analysts have recently weighed in on HOLX shares. Zacks Investment Research raised Hologic from a “sell” rating to a “hold” rating in a research note on Friday, February 24th. Barclays PLC set a $50.00 target price on Hologic and gave the stock a “buy” rating in a research note on Wednesday, April 5th. Bank of America Corp downgraded Hologic from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 15th. Needham & Company LLC raised Hologic from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research note on Wednesday, February 15th. Finally, BTIG Research reaffirmed a “buy” rating and set a $47.00 target price on shares of Hologic in a research note on Sunday, February 5th. Five research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Hologic has an average rating of “Buy” and an average target price of $47.54.

Several hedge funds have recently added to or reduced their stakes in the stock. Cleararc Capital Inc. raised its stake in Hologic by 1.1% in the first quarter. Cleararc Capital Inc. now owns 6,843 shares of the medical equipment provider’s stock worth $291,000 after buying an additional 77 shares during the last quarter. Compton Capital Management Inc. RI raised its stake in Hologic by 0.6% in the first quarter. Compton Capital Management Inc. RI now owns 16,810 shares of the medical equipment provider’s stock worth $715,000 after buying an additional 100 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in Hologic by 0.7% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 15,949 shares of the medical equipment provider’s stock worth $640,000 after buying an additional 104 shares during the last quarter. Advantus Capital Management Inc raised its stake in Hologic by 0.4% in the first quarter. Advantus Capital Management Inc now owns 27,936 shares of the medical equipment provider’s stock worth $1,189,000 after buying an additional 116 shares during the last quarter. Finally, Shell Asset Management Co. raised its stake in Hologic by 0.7% in the first quarter. Shell Asset Management Co. now owns 24,647 shares of the medical equipment provider’s stock worth $1,049,000 after buying an additional 182 shares during the last quarter. Institutional investors own 94.09% of the company’s stock.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

12 Month Chart for NASDAQ:HOLX

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.